Cingulate Inc.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is …
Biotechnology
US, Kansas City [HQ]
Growth Rates · Payout · Yield
Dividends Over Time
Growth Rates · Payout · Yield
Growth Rates
%
YoY
%
3Yr
%
5Yr
%
10Yr
Key Metrics
- -%
TTM Yield
- -
Average Days Gap
Series
% - -
Yield
0.00%
Payout Ratio
History
We could not find any dividend history for Cingulate Inc..